Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07363382 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer

Name: The Value of GRPR PET Imaging for Diagnosis and Staging in Prostate Cancer — clinical trial record (NCT07363382)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 1/2

SponsorFirst Affiliated Hospital of Fujian Medical University

Started2025-12-20

View on ClinicalTrials.gov ↗

First Affiliated Hospital of Fujian Medical University

56 trials monitored

See all monitored trials

Prostate Cancer

2,471 trials monitored

See 156 trials at risk

The gastrin-releasing peptide receptor (GRPR) is highly expressed in prostate cancer (77%-100%). Numerous studies have confirmed that GRPR PET imaging has emerged as a significant molecular imaging modality in prostate cancer, particularly serving as a complementary tool to PSMA PET for addressing cases with negative or insufficient PSMA expression. It demonstrates substantial value in initial staging (especially in intermediate- and high-risk patients), detecting sites of biochemical recurrence, assessing metastatic lesions (notably in mCRPC), and guiding treatment decisions. 68Ga-G21 and 68Ga-G23 are two novel molecular probes targeting GRPR. This study aims to evaluate their biodistribution and diagnostic performance in prostate cancer and compare them with 68Ga-PSMA-11 PET imaging.

Trial Details

NCT Number	NCT07363382
Lead Sponsor	First Affiliated Hospital of Fujian Medical University
Conditions	Prostate Cancer (Adenocarcinoma)
Enrollment	6 participants
Start Date	2025-12-20
Primary Completion	2026-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-01-23